echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Br J Cancer: miR-199b-5p-DDR1-ERK signaling pathline mediates emT processes to inhibit the metastasis of prostate cancer

    Br J Cancer: miR-199b-5p-DDR1-ERK signaling pathline mediates emT processes to inhibit the metastasis of prostate cancer

    • Last Update: 2020-12-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Prostate cancer (PCa), one of the most commonly diagnosed malignant tumors in men in Western countries, is the second leading cause of cancer-related deaths.
    2018, there will be about 1.3 million new confirmed PCa cases worldwide.
    , the incidence and mortality of prostate cancer have increased year by year.
    although cured prostatectomy or radiotherapy has been shown to be effective in controlling local PCa, there are still some patients with relapses or metastasis.
    there is currently no effective treatment for patients with metastasis PCa.
    , it is particularly important to better understand the underlying molecular mechanisms that promote PCa transfer, which will also facilitate the development of new therapies and the improved implementation of existing treatment options.
    MicroRNA (miRNA) is a small, endo-coding RNA with 17-23 nucleotides that inhibits transcriptional gene expression by binding to the target mRNA 3'-UTR.
    previous studies have shown that miRNA can be an important regulatory factor in the various biological processes in which tumors occur, invade and metascess.
    therefore, studying the role of miRNA in cancer and metastasis can help to better understand tumor occurrence.
    miR-199b-5p inhibits tumor growth and metastasis It is reported that miR-199b-5p is expressed in a variety of cancers, including hepatocellular carcinoma, renal cell carcinoma, breast cancer and acute myeloid leukemia, and plays a tumor suppression function in the growth, invasion and metastasis of tumor cells.
    , however, the clinical significance and role of miR-199b-5p in PCa is not clear.
    the study aims to study the expression status of miR-199b-5p in PCa and the relevant molecular mechanisms involved in the transfer of PCa through biometric analysis, functional loss and access experiments, and saving the rescue experiment.
    researchers found that miR-199b-5p's expression levels in metastatic PCa tissue and cells were significantly lower than normal prostate tissue, localized, weakly metastatic and androgen-dependent PCa cells, and normal prostate epithal cells.
    miR-199b-5p can significantly inhibit the proliferation, migration and invasion of PCa cells, and can inhibit the growth and metastasis of transplanted tumors.
    in PCa, DDR1 is a target mechanism study of miR-199b-5p, which shows that miR-199b-5p inhibits the expression of the gene by directly targeting the 3'-UTR region of DDR1, ultimately suppressing the superskin-interstate transformation (EMT)-related esoteric esoteric transformation (EMT) induced by the DDR1 activation ERK signal path.
    further studies showed that the total survival of patients with PCa with low miR-199b-5p expression levels was significantly shorter than in patients with PCa with high expression levels, indicating that the absence of miR-199b-5p was associated with poor prognostication in patients with PCa.
    addition, the expression level of DDR1 in PCa was increased and was significantly associated with the high Gleason classification of the disease, late pathological stages, tumor metastasis, and shorter total lifetimes.
    , the results reveal for the first time the anti-cancer function of miR-199b-5p in PCa invasion and metastasis.
    the study also identified a new mechanism for the signaling path of miR-199b-5p-DDR1-ERK to regulate EMT in PCa transfer.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.